MannKind Corporation, a biopharmaceutical company, announces the results of the experiments of their inhaled insulin product. The company has done an year long experiment. Finally they have come to the conclusion that the product is effective in controlling the blood-glucose levels and didn’t raise concerns about lung function.
MannKind said the results are from one of three major late-stage studies, with the others looking at long-term efficacy and safety. The company said it plans to submit the drug to the FDA by the end of the year or early in 2009.
Other companies like the Eli Lilly, Alkermes, Novo Nordisk are still working on the inhaled insulin.
Thus the product is one step ahead of the Pfizer made product Exubera. The product used to lower blood glucose down but the safety questions had to do with long-term use.
The MannKind product however, has to go a long way before make it to market.
Source: The Wall Street Journal